$LWAY

Lifeway Foods, Inc. (NASDAQ:LWAY) Short Interest Up 255.8% in May

Lifeway Foods (NASDAQ:LWAY) saw short interest rise 255.8% in May, reaching 1,030,606 shares as of May 15 versus 289,632 on April 30, with a 5.8-day days-to-cover ratio. The stock closed Friday at $23.83. On May 14, it reported Q1 EPS of $0.30 and revenue of $63.01M.

Original reporting
Published May 31, 2026, 4:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 31, 2026, 4:58 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Lifeway Foods, Inc. (NASDAQ:LWAY) Short Interest Up 255.8% in May — source image
Decision brief

The 30-second read

$LWAYNeutralMed
01

Why it matters

A 255.8% short-interest increase (to 1.03M shares) with 5.8 days-to-cover suggests shorts are relatively crowded; combined with a modest earnings beat, this can raise the probability of sharp intraday moves if sentiment shifts.

02

Market read

Traders may use the short-interest jump and days-to-cover as a near-term volatility/squeeze input, while monitoring whether the May 14 earnings beat changes expectations.

03

What to watch

The article doesn’t break down borrow availability, lender constraints, or whether the earnings beat changed forward estimates—those can dominate squeeze outcomes versus short-interest alone.

Relevance 8/10Novelty 6/10Timing: after-hours / end-of-day positioning update for May short interest and post–May 14 earnings context

Background

Short interest is measured as of May 15 (vs April 30) and is paired with the company’s most recent earnings release on May 14.

Company-level read

Ticker impact

$LWAYNeutralMedium confidence
Context

Article reports Lifeway Foods’ short interest jumped 255.8% in May and cites days-to-cover of 5.8, plus May 14 earnings results.

Expected impact

Choppy-to-volatile trading bias; potential short-covering pop if momentum improves, but no clear fundamental re-rating signal beyond the earnings beat.

Evidence & confidence

The piece provides concrete positioning data (short interest, days-to-cover) and a specific earnings datapoint (EPS and revenue vs consensus), but it’s a recap-style market-microstructure update without a new catalyst like guidance or a deal.

Market effects

Limited sector read-through; this is primarily single-name positioning and recent earnings context for a niche cultured-dairy/probiotics player.

None material beyond US small/mid-cap sentiment.

None.

Counterpoint

Short interest can rise even if fundamentals are improving; the move may reflect hedging or liquidity/float dynamics rather than a bearish thesis.

Key entities

  • Lifeway Foods, Inc.

    Subject of the article; short interest surged and it recently reported Q earnings (EPS $0.30; revenue $63.01M).

  • Divisadero Street Capital

    Disclosed purchase of 33,174 shares on May 15 at an average $25.27.

  • Edward Smolyansky

    Disclosed sale of 24,000 shares on May 15 at an average $24.87.

Related articles

$SMCIMed

Super Micro Computer Landed $60 Billion in Orders Last Quarter, but Trades at Just $30

Super Micro Computer (SMCI) said it booked over $60B in new orders in its fiscal Q4 ended June 30, lifting backlog to a record. It guided FY2026 revenue near the low end of $11B to $12.5B and gross margins at 15% to 17%. The company also plans $7B equity financing for AI server orders, noting some orders may not be firm and citing an independent review tied to export control issues.

$CSCOMed

Cisco Stock Is Finally Pricing In A New Growth Story

Cisco raised full-year revenue and EPS guidance on May 13, 2026, citing AI infrastructure demand. Management expects about $9 billion in FY2026 AI orders from hyperscalers and cited 5 hyperscaler design wins in Q3. Cisco shares rose about 20% since, with product orders up 19% YoY excluding hyperscaler growth. Options imply 41% IV ahead of the next catalyst.

$RMDMed

Off Into Weekend, As Early Work Undone

ResMed (ASX:RMD) fell 8.29% on Friday and is 3.09% lower for the week after a strong run. The company reported a solid Q4, with FY26 revenue up 10% to $5.7b, gross Q4 margin 62.3%, FY EPS up 17% to $11.17, and a 10% dividend increase to $0.66. Morgan Stanley downgraded to Equal Weight and cut its price target, citing cooling growth and Philips’ potential US return in 2027.